Tuberculosis Elimination and Laboratory Cooperative Agreement
This NOFO supports the continued focus on identifying and curing persons with TB disease, but also includes the addition of a targeted testing and treatment strategy for LTBI. TB disproportionately affects certain populations, including those who are non-U.S.-born, with HIV infection or diabetes, experiencing homelessness, who are incarcerated, and who use illicit substances. The TB incidence rate among non-U.S.-born persons in 2017 was approximately 15 times greater compared to U.S.-born persons, and the percentage of TB cases occurring in non-U.S.-born persons continues to increase, reaching 70.1% in 2017. Achieving TB elimination in the United States will require focusing on persons in these high-risk groups – an approach that is reinforced by this NOFO. CDC is continuing a 30-year strategy of funding TB programs through cooperative agreements (CoAgs). The primary responsibility for developing and implementing TB P&C and laboratory activities rests with state and local health departments, and this funding is intended to complement those efforts. The intent of this funding is not to supplant or reduce state and local investment in TB control activities and responsibilities (e.g., provision of medications, in-patient care, and health department facilities).